Spherix (SPEX) said initial data from a late-stage trial of its type 2 oral diabetes drug Naturlose showed a significant drop in blood glucose level, the trial's main goal. The biotech said it remained on target to finish the trial and submit a new drug application in '10. Shares more than doubled intraday before closing just 3 cents higher at 2.03.
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here